share_log

LifeWallet Reveals $3.1M Settlement In Latest Pharmaceutical Antitrust Case

Benzinga ·  Aug 19 14:36
  • Company also announces a drive to secure agreements with health plans, property & casualty insurers, attorneys, and healthcare providers, including hospital systems
  • This subscription licensing is expected to generate revenue through fees charged on savings from unnecessary Medicare secondary payments
  • This is all part of LifeWallet's clearinghouse system, through its exclusive healthcare partnership with Palantir Technologies, Inc.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment